| Chenxi Yin,Chang Jiang,Fangxin Liao,Yuming Rong,Wenzhuo He,Xiuyu Cai,Guifang Guo,Huijuan Qiu,Xuxian Chen,Bei Zhang,Liangping Xia. The efficacy of bevacizumab in Chinese patientswith metastatic colorectal cancer and its effect indifferent line setting. Oncol Transl Med, 2014, 13: 169-173. |
| The efficacy of bevacizumab in Chinese patientswith metastatic colorectal cancer and its effect indifferent line setting |
| |
| View Full Text View/Add Comment Download reader |
| KeyWord:bevacizumab; chemotherapy; metastatic colorectal cancer; efficacy |
| Author Name | Affiliation | | Chenxi Yin | State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center
VIP Region, Sun Yat-sen University Cancer Center
Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China | | Chang Jiang | State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center
VIP Region, Sun Yat-sen University Cancer Center
Collaborative Innovation Center for Cancer Medicine, Guangzhou 510061, China | | Fangxin Liao | State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center
VIP Region, Sun Yat-sen University Cancer Center
Collaborative Innovation Center for Cancer Medicine, Guangzhou 510062, China | | Yuming Rong | State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center
VIP Region, Sun Yat-sen University Cancer Center
Collaborative Innovation Center for Cancer Medicine, Guangzhou 510063, China | | Wenzhuo He | State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center
VIP Region, Sun Yat-sen University Cancer Center
Collaborative Innovation Center for Cancer Medicine, Guangzhou 510064, China | | Xiuyu Cai | State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center
VIP Region, Sun Yat-sen University Cancer Center
Collaborative Innovation Center for Cancer Medicine, Guangzhou 510065, China | | Guifang Guo | State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center
VIP Region, Sun Yat-sen University Cancer Center
Collaborative Innovation Center for Cancer Medicine, Guangzhou 510066, China | | Huijuan Qiu | State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center
VIP Region, Sun Yat-sen University Cancer Center
Collaborative Innovation Center for Cancer Medicine, Guangzhou 510067, China | | Xuxian Chen | State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center
VIP Region, Sun Yat-sen University Cancer Center
Collaborative Innovation Center for Cancer Medicine, Guangzhou 510068, China | | Bei Zhang | State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center
VIP Region, Sun Yat-sen University Cancer Center
Collaborative Innovation Center for Cancer Medicine, Guangzhou 510069, China | | Liangping Xia | State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center
VIP Region, Sun Yat-sen University Cancer Center
Collaborative Innovation Center for Cancer Medicine, Guangzhou 510070, China |
|
| Hits: 7276 |
| Download times: 7876 |
| Abstract: |
| Objective: We aimed to evaluate the effect of bevacizumab in the palliative treatment of Chinese metastatic colorectal cancer (mCRC) and its efficacy in different lines. Methods: Patients of mCRC treated with bevacizumab or not at Sun Yat-sen University Cancer Center from 2005 to 2013 were recruited as the study group and control group. The endpoints were objective response rate (ORR), disease control rate (DCR), overall survival (OS) and progression free survival (PFS). The OS and PFS of first-, second- and third-line treatment groups were compared between study group and control group. Results: The median PFS of the study and the control group were 8.2 months (7.0–9.4 months), 5.7 months (4.7–6.6 months), P = 0.001; OS were 26 months (5.4–130.5 months), 18 months (16.6–19.4 months), P < 0.001, respectively. The ORR and DCR of first-, second- and third-line were 30.3% (20/66), 20% (6/30), 17.6% (3/17) and 97% (64/66), 86.7% (26/30), 100% (17/17). In the first-line chemotherapy group, the OS of the study group and the control group were 22.9 (5.4–96.7) months and 18 (16.6–19.4) months (P < 0.001); PFS were 9.4 (8.4–10.4) months and 5.7 (4.7–6.6) months (P < 0.001), respectively. While in the second- and third-line setting, only OS were statistically different, PFS had no significant difference. Conclusion: The combination of bevacizumab and chemotherapy had a promising short-term and long-term efficacy in Chinese mCRC patients than those without bevacizumab regimens, and the effect could be better reflected in the first-line treatment. |
| Close |
|
|
|